Fiche société
Base Therapeutics (Shanghai) Co., Ltd.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications3liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| NK510 : allogeneic genetic modified NKThis is an investigator-initiated, open-label, single-arm study to determine safety and preliminary efficacy of NK510 for the treatment of patients with refractory systemic lupus erythematosus (SLE) in China. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| NK510 : allogeneic genetic modified NKThis is an investigator-initiated, open-label, single-arm study to determine safety and preliminary efficacy of NK510 for the treatment of patients with refractory systemic lupus erythematosus (SLE) in China. | Lupus | Phase 1 | Thérapie cellulaire | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| NK510 : allogeneic genetic modified NK | Lupus | Phase 1 | NCT07083349 | NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus | TERMINATED |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| NK510 : allogeneic genetic modified NK | High affinity CD16 allogeneic NK cell therapy, AB-101, enhances antibody-mediated cytotoxicity in B-cell driven diseases. | Cytotherapy | ||
| NK510 : allogeneic genetic modified NK | Emerging frontiers in adoptive cell therapies: engineering innovations, current challenges, and manufacturing perspectives. | Molecular biology reports | ||
| NK510 : allogeneic genetic modified NK | Natural killer cell-based therapy for hepatocellular carcinoma (HCC): A literature review. | Medical oncology (Northwood, London, England) |